Comparison of the chemical constituents and anti-Alzheimer’s disease effects of Uncaria rhynchophylla and Uncaria tomentosa
Open Access
- 27 October 2021
- journal article
- research article
- Published by Springer Nature in Chinese Medicine
- Vol. 16 (1) , 1-15
Abstract
Background: Uncaria tomentosa, which has similar chemical constituents with Uncaria rhynchophylla, has been reported to alleviate cognitive impairments in Alzheimer’s disease (AD) animal models. This study aimed to compare the chemical constituents and anti-AD effect of the ethanol extracts of U. tomentosa (UTE) and U. rhynchophylla (URE). Methods: The high-performance liquid chromatography (HPLC) was used to compare the chemical constituents of UTE and URE. Streptozotocin (STZ) was intracerebroventricularly (ICV) injected into adult male Sprague–Dawley (SD) rats to establish AD model. UTE (400 mg/kg) or URE (400 mg/kg) was administrated intragastrically once daily to the rats for 6 consecutive weeks. Morris water maze (MWM) test was conducted to assess the neurological functions in the STZ-induced AD rats. The brain tissues of the rats were harvested for further biochemical assay. Results: The MWM test results showed both UTE and URE could significantly improve the learning and memory impairments induced by STZ in rats. Both UTE and URE could significantly inhibit the hyperphosphorylation of tau protein, reduce the elevated levels of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α), enhance activities of antioxidant enzymes (SOD, CAT and GPx) and increase the protein expression of HO-1. In addition, UTE could decrease the malondialdehyde (MDA) level. Furthermore, both UTE and URE significantly enhanced Akt activation, down regulated the activation of glycogen synthase kinase 3β (GSK-3β), and induced the nuclear translocation of Nrf2 in the STZ-induced AD rats. Conclusions: UTE and URE contained similar chemical constituents. We found for the first time that both of them could ameliorate cognitive deficits in the STZ-induced AD rats. The underlying molecular mechanism involve suppression of tau hyperphosphorylation, anti-oxidant and anti-neuroinflammation via modulating Akt (Ser473)/GSK3β (Ser9)-mediated Nrf2 activation. These findings amply implicate that both of UTE and URE are worthy of being developed clinically into pharmaceutical treatment for AD.Keywords
Funding Information
- li dak sum yip yio chin r & d centre for chinese medicine, the chinese university of hong kong
This publication has 80 references indexed in Scilit:
- Role of genes linked to sporadic Alzheimer’s disease risk in the production of β-amyloid peptidesProceedings of the National Academy of Sciences, 2012
- Identification of oligomers at early stages of tau aggregation in Alzheimer's diseaseThe FASEB Journal, 2012
- Bioassay-Guided Isolation of Neuroprotective Compounds fromUncaria rhynchophyllaagainst Beta-Amyloid-Induced NeurotoxicityEvidence-Based Complementary and Alternative Medicine, 2012
- Protective Effect of Isorhynchophylline Against β-Amyloid-Induced Neurotoxicity in PC12 CellsCellular and Molecular Neurobiology, 2011
- Alzheimer's DiseaseNew England Journal of Medicine, 2010
- Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2009
- Pharmacology and therapeutic uses of cat’s clawAmerican Journal of Health-System Pharmacy, 2009
- The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspectiveJournal of Neuroinflammation, 2008
- Expression of Nrf2 in Neurodegenerative DiseasesJournal of Neuropathology & Experimental Neurology, 2007
- Interleukin-1 and neuronal injuryNature Reviews Immunology, 2005